The Genomic AI Stack: 23andMe and HealthEx Bring Records Into the Health Summary

The Genomic AI Stack: 23andMe and HealthEx Bring Records Into the Health Summary

For the first time, a major consumer genetics company is using the federal TEFCA framework to pull a member's complete medical history directly into their genetic profile. On May 20, 23andMe announced a partnership with HealthEx that lets members link diagnoses, lab results, medications, and care history to the AI Health Summary the company launched earlier this year. The integration moves consumer genetics from a static report on predispositions to something closer to a continuously updated picture of where someone actually stands, with their genome as the baseline.

The partnership matters beyond 23andMe. HealthEx is the same infrastructure layer Anthropic selected in January when it launched Claude for Healthcare, making HealthEx the first consumer health record integration for Claude. With 23andMe now on the same rails, a pattern is forming. The companies building consumer-facing AI health products are converging on a single consent and access stack, and that stack runs on TEFCA Individual Access Services.

What 23andMe Built

The 23andMe AI Health Summary launched to Beta Testing Program members in March 2026. It combines genetic results, blood labs, and lifestyle data into a single view, surfacing the areas the company's models flag as most worth attention. The framing in 23andMe's own materials is direct about what makes the product different from a general-purpose health chatbot. Most AI health tools are trained on population averages. The Health Summary benchmarks an individual against what 23andMe calls their genetic peers, accounting for ancestry and genetic risk, not just age and gender.

That positioning had a missing piece. Genetics tells a member what they are predisposed to. Without clinical history, the system has no way to know what has actually happened in that member's body, what conditions they currently manage, what their recent labs show, or what medications they take. The HealthEx integration fills that gap. Beta members will be able to connect their complete medical history across providers, and the Health Summary will use that clinical record alongside genetic and lifestyle data to produce its insights.

The consumer-facing capabilities are planned for availability this summer, starting with the connection of clinical records into the genetic profile and expanding from there.

The Infrastructure: TEFCA and Individual Access Services

HealthEx provides the connective tissue. The company operates as an Individual Access Services provider under the Trusted Exchange Framework and Common Agreement, a federal interoperability framework that has matured rapidly since the first Qualified Health Information Networks were designated in December 2023. Individual Access Services is the specific TEFCA exchange purpose that lets patients direct their own records to apps of their choice, with a workflow built around identity verification, patient matching, and explicit consent.

In practical terms, a 23andMe member who wants to add their clinical history will verify their identity, grant consent, and HealthEx will retrieve records from the participating provider organizations where that person has received care. HealthEx already touts the ability to pull records from more than 50,000 provider organizations through its TEFCA connections. The patient can revoke access at any time, and HealthEx maintains audit trails of what was accessed and when.

23andMe is one of the first consumer genetics companies to use this national framework for automated medical record access. That distinction matters because the alternative is what consumers have lived with for years: logging into one patient portal at a time, downloading PDFs, and manually trying to make sense of records that were never designed to talk to each other. Industry estimates suggest the average American patient has records spread across multiple portals, with no native interoperability between them. TEFCA Individual Access Services is the closest thing to a national solution.

Why HealthEx Keeps Showing Up

Anthropic chose HealthEx in January to bring personal medical records into Claude through the Model Context Protocol, with Claude Pro and Max subscribers able to link their records from more than 50,000 provider organizations. 23andMe is using the same provider for the same fundamental job, with a different consumer surface.

The repetition is informative. Two of the most visible consumer AI health launches of 2026 have routed their record-access infrastructure through the same identity, consent, and retrieval stack. Building that stack independently is expensive and slow. It requires QHIN contracts, identity verification certified to federal standards (HealthEx uses CLEAR for IAL2/AAL2 identity proofing), FHIR-based data normalization, and computable consent infrastructure that lets a user revoke access in a way that propagates correctly downstream. Companies whose core product is an AI model or a genetic database have little reason to rebuild that.

For HealthEx, the strategic position is clear. The company describes its model as a digital health wallet, and the wallet metaphor extends. If a consumer has already verified their identity and connected their records to HealthEx for one platform, adding another requires no new setup. The same wallet works at the next door. CEO Dr. Priyanka Agarwal and her team appear to be building what amounts to a shared substrate for consumer-controlled health data, with the AI companies and the genetics companies as the first wave of tenants.

The Bigger Shift in Consumer Health AI

The earlier model of consumer health AI was a chatbot you could ask questions. The new model is a system with access to your actual data, capable of producing personalized output instead of generic answers. That shift only works if the data plumbing exists, and until very recently, it largely did not for clinical records. TEFCA's maturation, combined with the federal push under CMS toward a more patient-centric data ecosystem, has changed the timing.

23andMe's framing of the difference is worth quoting from its own product post, in summary: dumping data into a chatbot might tell you that walking 10,000 steps today is great, but without your genetic data, those 10,000 steps might not be enough to move the needle on your specific risk. The product's value proposition rests on having both layers, and the HealthEx integration adds the third: what has actually happened to you clinically.

There are open questions. Privacy concerns have followed 23andMe through the bankruptcy and reacquisition by Anne Wojcicki's nonprofit TTAM Research Institute, which closed in July 2025 for $305 million. TTAM has made specific commitments around customer choice, transparency, and the handling of genetic data in any future ownership transition. Adding clinical records expands the data footprint, and consumer trust will depend on whether the consent and revocation mechanisms work as advertised in practice, not just in the marketing copy. The same scrutiny applies to every platform using HealthEx as its access layer.

There is also the research dimension. 23andMe's research operations have always depended on the willingness of consented members to contribute data for genetic discovery. Adding real-world clinical records to that dataset creates new possibilities for understanding how genetic predispositions actually manifest across populations. It also raises the bar for consent design, because the dataset becomes substantially richer about each individual contributor.

What to Watch

A few markers will tell us whether this integration becomes a template or a footnote.

The first is uptake. The Health Summary is currently in beta, and the clinical records integration arrives this summer. How many members opt in, how quickly, and how often they engage with the resulting insights will indicate whether consumers actually want this kind of synthesis or whether the demand is narrower than the marketing suggests.

The second is whether other consumer health platforms follow the same path. If the next several major launches in consumer AI health all sit on TEFCA Individual Access Services, with HealthEx or a small number of similar providers in the connector role, the architectural pattern becomes the standard. If not, fragmentation continues.

The third is regulatory. The American Hospital Association raised concerns in April about the proposed updates to the TEFCA Individual Access Services standard operating procedure, citing patient privacy and provider compliance risks. How those tensions resolve will shape how easily consumer-facing apps can keep adding new data sources, and how confident hospitals feel about responding to IAS queries at scale.

For now, 23andMe has done something genuinely new. It has paired the genome with the medical record, in a system designed for consumers to actually use, with an AI layer designed to produce personalized output rather than generic averages. The plumbing underneath, courtesy of HealthEx and TEFCA, is the part most users will never see. It is also the part that made any of this possible.

---

Click image to read the previous article